Navigation Links
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Date:12/9/2008

SAN FRANCISCO, Dec. 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), today announced preliminary data from its recently completed multi-center, open-label, ascending-dose Phase 1b clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients with heart failure. Results of this study showed:

  • CD-NP was well tolerated at doses of up to 20 ng/kg/min
  • Blood pressure effects were dose dependent and well characterized
  • CD-NP demonstrated diuretic effects comparable to furosemide
  • CD-NP produced statistically significant changes on biomarkers consistent with enhanced renal function

These positive results are supportive of further study to fully validate proof-of-concept of CD-NP in a Phase 2b clinical trial planned to begin in 2009.

About the Study

The objectives of the Phase 1b study were to establish the maximum tolerated dose (MTD) and to assess the pharmacodynamic effects of CD-NP on blood pressure and renal function in stable heart failure patients. Patients with NYHA Class II or Class III heart failure, ejection fraction <40% and current signs of fluid overload were included in the study. In this dose escalation trial, four cohorts were administered a single 24-hour infusion of CD-NP at a dose of either 3 (n=6), 10 (n=6), 20(n=6) or 30 ng/kg/min (n=2). During the infusion of CD-NP, furosemide and vasoactive therapies were withheld.

Effects on Blood Pressure

The effects on blood pressure were dose-dependent. During a 24-hour infusion of CD-NP at doses of 3, 10 and 20 ng/kg/min, mean reductions in Mean Arterial Pressure were 2.2, 8.9 and 13.2 mmHg respectively.

CD-NP was well-tolerated at dos
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
9. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
10. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
11. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... Triangle Park, NC (PRWEB) January 14, 2014 ... company focusing on ultra-sensitive POC diagnostic platforms and novel disease ... their first round of financing netting a total of $690,000. ... outside equity capital in the company. This group of private ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Focus on Critical Industry Issues -- DUBAI, UAE, September 8, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... YORK, Sept. 7 Reportlinker.com announces that a ... catalogue: Biotechnology Pharmaceutical Market in ... Biotechnology Pharmaceutical Market in US ... Pharmaceutical market to grow at a CAGR of ...
... Inc. (OTC Bulletin Board: FCSC ), a ... therapies for aesthetic, medical and scientific applications, announced today ... to its scientific advisory board. In addition to being ... a biotechnology and genetic research expert. Dr. Gruenwald also ...
Cached Biology Technology:Cold Chain MENA 2010 to Focus on Critical Industry Issues 2Cold Chain MENA 2010 to Focus on Critical Industry Issues 3Cold Chain MENA 2010 to Focus on Critical Industry Issues 4Cold Chain MENA 2010 to Focus on Critical Industry Issues 5Cold Chain MENA 2010 to Focus on Critical Industry Issues 6Reportlinker Adds Biotechnology Pharmaceutical Market in US -2013 2Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board 2Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board 3
(Date:4/23/2014)... TX (4/23/14) -- Researchers have found evidence of ... factors that increase aggressive behavior in children, especially ... not all children exposed to prenatal smoking will ... will not," said Brian Boutwell, Assistant Professor at ... and senior author on the study. "One ...
(Date:4/23/2014)... away from using triclosan as an antimicrobial ingredient in ... now scientists are reporting new evidence that appears to ... journal Chemical Research in Toxicology , found that ... promoted the growth of human breast cancer cells in ... Kyung-Chul Choi and colleagues note that hormonal imbalances seem ...
(Date:4/23/2014)... comprehensive study to date of the family of ... effective vaccine strategies and reveals surprising findings about ... could alter public health strategies to control this ... year. , Genomic analysis of 343 strains of ... the world collected over the last 100 years ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2
... Scheduling more physical education time in schools does not ... research that discovered those who got lots of timetabled ... while those who got little at school made up ... The scientists, who presented their research Thursday at the ...
... Inc. (Nasdaq: AWRE ), a leading supplier of ... its first quarter ended March 31, 2009. Revenues for ... of 22% compared to $5.9 million in the same quarter ... and diluted net income per share in accordance with U.S. ...
... Desert environments are characterized by poor vegetative cover, ... conditions. In this context, the land resources of ... are subjected to various land degradation stresses, including ... sustain the land resources of Abu Dhabi Emirate, ...
Cached Biology News:Study finds children's activity levels not influenced by more PE time in school 2Aware, Inc. Reports First Quarter 2009 Financial Results 2Aware, Inc. Reports First Quarter 2009 Financial Results 3Aware, Inc. Reports First Quarter 2009 Financial Results 4Aware, Inc. Reports First Quarter 2009 Financial Results 5Aware, Inc. Reports First Quarter 2009 Financial Results 6Wind, salt and water are leading indicators of land degradation in Abu Dhabi 2
...
Human Cystatin A MAb (Clone 224705)...
Corticoliberin...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Biology Products: